BPC-157 and Ipamorelin Together: What Is Known
BPC-157 and Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 7 results, 2 Oct 2026).
Side by side
Showing 13 of 13 fields where the two differ.
| Field | BPC-157 | Ipamorelin |
|---|---|---|
| Class | Gastric pentadecapeptide | GHRP (ghrelin receptor agonist) |
| Also called | BPC, body protection compound, Pentadecapeptide BPC 157 | ipa, ipam |
| Category | Healing & recovery | Growth hormone |
| FDA status | PCAC voted 8–6 for 503A (Jul 2026) | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition. | Prohibited by WADA (S2.2.4)Ipamorelin is named as a growth hormone secretagogue in S2.2.4, prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 |
| Evidence strength | Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143 | Human RCT evidence, 4 of 4Strongest: International journal of colorectal disease 2014, PMID 25331030 |
| Human studies we summarised | 3 human (0 randomized or controlled) of 25 summarised | 2 human (2 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 2 mg, 5 mg, 10 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
BPC-157 human reports are retrospective
In a retrospective chart review of BPC 157 knee injections, 11 of the 12 patients in one group reported significant knee-pain improvement, with no control group.[17]
The systematic review found 35 preclinical studies and only 1 clinical study.[18]
Ipamorelin was tested in surgery patients
In patients recovering from bowel surgery, ipamorelin did not significantly shorten time to the first tolerated meal: 25.3 versus 32.6 h (p = 0.15).[13]
Tested together?
The dataset search for BPC-157 with ipamorelin returned 7 PubMed records, none classed as a study of the pair.
Calculated from pubmed query ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (ipamorelin[tiab]); search date 2026-10-02; records returned 7; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key bpc-157__ipamorelin); no arithmetic applied.
WADA names ipamorelin as an example of a growth hormone secretagogue.[3]
WADA's S0 class text lists BPC-157 among its examples.[3]
Common questions
Can you take BPC-157 and ipamorelin together?
No study of the two was classed as relevant; the cached evidence covers each one separately.[13]
BPC-157 ipamorelin stack: is there evidence for it?
The sources contain no trial of the stack; the BPC-157 human data are retrospective and the ipamorelin trial studied post-surgery bowel recovery.[17]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 5Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 7Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 8Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 9Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 10Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 11Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 12Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 13Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 14The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 15PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (ipamorelin[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 17Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
- 18Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
Found an error? Report a correction.